Word

Status

Dead

Status Code

606

Status Date

Monday, April 17, 2023

Serial Number

88202403

Mark Type

2000

Filing Date

Wednesday, November 21, 2018

Published for Opposition

Tuesday, January 21, 2020

Abandoned Date

Monday, April 17, 2023

Trademark Owner History

Cyclerion Therapeutics, Inc. - Owner At Publication

Classifications

5 Pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds, namely, preparations that stimulate guanylate cyclases (sGC), increase the concentration of nitric oxide (NO), increase the concentration of cyclic guanosine monophosphate (cGMP), upregulate the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway, or utilize a synergistic interaction of the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway with a complementary signaling pathway; Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds

The mark consists of an incomplete circular design element comprised of 23 separate triangular shapes.
C
Color is not claimed as a feature of the mark.

Trademark Events

Apr 17, 2023

Abandonment Notice E-Mailed - No Use Statement Filed

Apr 17, 2023

Abandonment - No Use Statement Filed

Oct 4, 2022

Notice Of Approval Of Extension Request E-Mailed

Oct 3, 2022

Sou Extension 5 Granted

Aug 31, 2022

Sou Extension 5 Filed

Aug 31, 2022

Sou Teas Extension Received

Mar 3, 2022

Notice Of Approval Of Extension Request E-Mailed

Feb 28, 2022

Sou Extension 4 Granted

Feb 28, 2022

Sou Extension 4 Filed

Feb 28, 2022

Sou Teas Extension Received

Sep 16, 2021

Notice Of Approval Of Extension Request E-Mailed

Sep 14, 2021

Sou Extension 3 Granted

Sep 14, 2021

Sou Extension 3 Filed

Sep 14, 2021

Sou Teas Extension Received

Mar 10, 2021

Notice Of Approval Of Extension Request E-Mailed

Mar 8, 2021

Sou Extension 2 Granted

Mar 8, 2021

Sou Extension 2 Filed

Mar 8, 2021

Sou Teas Extension Received

May 19, 2020

Notice Of Approval Of Extension Request E-Mailed

May 15, 2020

Sou Extension 1 Granted

May 15, 2020

Sou Extension 1 Filed

May 15, 2020

Sou Teas Extension Received

May 13, 2020

Corrected Noa E-Mailed

May 12, 2020

Divisional Processing Complete

Apr 26, 2020

Divisional Request Received

May 12, 2020

Case Assigned To Intent To Use Paralegal

Apr 26, 2020

Teas Request To Divide Received

Mar 17, 2020

Noa E-Mailed - Sou Required From Applicant

Jan 21, 2020

Official Gazette Publication Confirmation E-Mailed

Jan 21, 2020

Published For Opposition

Jan 1, 2020

Notification Of Notice Of Publication E-Mailed

Dec 18, 2019

Assigned To Lie

Dec 16, 2019

Approved For Pub - Principal Register

Dec 16, 2019

Examiner's Amendment Entered

Dec 16, 2019

Notification Of Examiners Amendment E-Mailed

Dec 16, 2019

Examiners Amendment E-Mailed

Dec 16, 2019

Examiners Amendment -Written

Jul 9, 2019

Notification Of Final Refusal Emailed

Jul 9, 2019

Final Refusal E-Mailed

Jul 9, 2019

Final Refusal Written

Jun 19, 2019

Teas/Email Correspondence Entered

Jun 19, 2019

Correspondence Received In Law Office

Jun 19, 2019

Teas Response To Office Action Received

Dec 19, 2018

Notification Of Non-Final Action E-Mailed

Dec 19, 2018

Non-Final Action E-Mailed

Dec 19, 2018

Non-Final Action Written

Dec 18, 2018

Assigned To Examiner

Dec 14, 2018

Notice Of Design Search Code E-Mailed

Dec 13, 2018

New Application Office Supplied Data Entered

Nov 24, 2018

New Application Entered